risperidone has been researched along with Callous-Unemotional Traits in 30 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examining treatment effects for attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder (CD) symptoms and peer aggression, symptom-induced impairment, and informant discrepancy." | 9.19 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. ( Aman, MG; Arnold, LE; Austin, AB; Baker, JL; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, HL; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "Risperidone has been found efficacious for decreasing severe tantrums, aggression, and self-injurious behavior in children and adolescents with autistic disorder (autism)." | 9.11 | Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. ( Aman, MG; Arnold, LE; Chuang, SZ; Davies, M; Ghuman, JK; Gonzalez, NM; Hollway, J; Koenig, K; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "The present study aimed to analyse the effect of risperidone on a priori defined core aggression items." | 9.11 | Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. ( Aman, MG; Armenteros, JL; Binder, CE; Hew, H; Kusumakar, V; LeBlanc, JC; Wang, JS, 2005) |
| "Risperidone was superior to placebo in ameliorating aggression on most measures." | 9.09 | A double-blind pilot study of risperidone in the treatment of conduct disorder. ( Blumer, JL; Branicky, LA; Findling, RL; Lemon, E; McNamara, NK; Schluchter, MD, 2000) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 8.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 7.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| " Safety measures included body mass index, serum prolactin, extrapyramidal adverse effects, and electrocardiogram." | 6.80 | Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. ( Masi, G; Milone, A; Pisano, S; Stawinoga, A; Veltri, S, 2015) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 6.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| "In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examining treatment effects for attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder (CD) symptoms and peer aggression, symptom-induced impairment, and informant discrepancy." | 5.19 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. ( Aman, MG; Arnold, LE; Austin, AB; Baker, JL; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, HL; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "Risperidone has been found efficacious for decreasing severe tantrums, aggression, and self-injurious behavior in children and adolescents with autistic disorder (autism)." | 5.11 | Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. ( Aman, MG; Arnold, LE; Chuang, SZ; Davies, M; Ghuman, JK; Gonzalez, NM; Hollway, J; Koenig, K; Martin, A; McCracken, JT; McDougle, CJ; McGough, JJ; Posey, DJ; Ritz, L; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2005) |
| "The present study aimed to analyse the effect of risperidone on a priori defined core aggression items." | 5.11 | Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. ( Aman, MG; Armenteros, JL; Binder, CE; Hew, H; Kusumakar, V; LeBlanc, JC; Wang, JS, 2005) |
| "To determine whether risperidone is effective in reducing symptoms of disruptive behaviors (such as aggression, impulsivity, defiance of authority figures, and property destruction) associated with conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified in children with subaverage IQs." | 5.10 | Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. ( Aman, M; Binder, C; Carroll, A; Fisman, S; Snyder, R; Turgay, A, 2002) |
| "Risperidone was superior to placebo in ameliorating aggression on most measures." | 5.09 | A double-blind pilot study of risperidone in the treatment of conduct disorder. ( Blumer, JL; Branicky, LA; Findling, RL; Lemon, E; McNamara, NK; Schluchter, MD, 2000) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| " Here, authors report on an interesting case of risperidone-induced pancreatitis in a child with ADHD comorbid with conduct disorder." | 4.12 | Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD. ( Alamiri, B; Naguy, A; Roshdy, R, 2022) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 3.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| " The aims of this study were to investigate the effectiveness and adverse effects of LAIR in children and adolescents with conduct disorder, bipolar disorder, and schizophrenia." | 2.84 | Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. ( Ceylan, MF; Cop, E; Erdogan, B; Tural Hesapcioglu, S, 2017) |
| " Safety measures included body mass index, serum prolactin, extrapyramidal adverse effects, and electrocardiogram." | 2.80 | Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder. ( Masi, G; Milone, A; Pisano, S; Stawinoga, A; Veltri, S, 2015) |
| " The results from the literature underline the necessity of caution and patient monitoring when risperidone dosing is modified during methylphenidate therapy." | 2.72 | Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. ( Burden, AM; Stämpfli, D; Weiler, S, 2021) |
| " Safety and tolerability were good overall, with the number of adverse events (AEs) decreasing in the extension trial, compared to the original trial." | 2.72 | Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. ( Augustyns, I; Croonenberghs, J; Eerdekens, M; Reyes, M, 2006) |
| "Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint, as well as on the Aberrant Behavior Checklist subscales for irritability, lethargy/social withdrawal, and hyperactivity; the Behavior Problems Inventory aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; and the Clinical Global Impression change score." | 2.70 | Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. ( Aman, MG; De Smedt, G; Derivan, A; Findling, RL; Lyons, B, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 4 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wozniak, J | 1 |
| DiSalvo, M | 1 |
| Farrell, A | 1 |
| Yule, A | 1 |
| Joshi, G | 1 |
| Cook, E | 1 |
| Faraone, SV | 1 |
| Biederman, J | 1 |
| Hodgins, GE | 1 |
| Winsor, K | 1 |
| Barnhill, J | 1 |
| Naguy, A | 1 |
| Roshdy, R | 1 |
| Alamiri, B | 1 |
| Stämpfli, D | 1 |
| Weiler, S | 1 |
| Burden, AM | 1 |
| Ceylan, MF | 1 |
| Erdogan, B | 1 |
| Tural Hesapcioglu, S | 1 |
| Cop, E | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Gnanavel, S | 1 |
| Joseph, HM | 1 |
| Farmer, C | 1 |
| Kipp, H | 1 |
| Kolko, D | 1 |
| Aman, M | 2 |
| McGinley, J | 1 |
| Arnold, LE | 3 |
| Gadow, KD | 2 |
| Findling, RL | 5 |
| Molina, BSG | 1 |
| Khan, S | 1 |
| Down, J | 1 |
| Aouira, N | 1 |
| Bor, W | 1 |
| Haywood, A | 1 |
| Littlewood, R | 1 |
| Heussler, H | 1 |
| McDermott, B | 1 |
| Glennon, J | 1 |
| Purper-Ouakil, D | 1 |
| Bakker, M | 1 |
| Zuddas, A | 1 |
| Hoekstra, P | 1 |
| Schulze, U | 1 |
| Castro-Fornieles, J | 1 |
| Santosh, PJ | 1 |
| Arango, C | 1 |
| Kölch, M | 1 |
| Coghill, D | 1 |
| Flamarique, I | 1 |
| Penzol, MJ | 1 |
| Wan, M | 1 |
| Murray, M | 1 |
| Wong, IC | 1 |
| Danckaerts, M | 1 |
| Bonnot, O | 1 |
| Falissard, B | 1 |
| Masi, G | 2 |
| Fegert, JM | 1 |
| Vicari, S | 1 |
| Carucci, S | 1 |
| Dittmann, RW | 1 |
| Buitelaar, JK | 1 |
| Javelot, H | 1 |
| Glay-Ribau, C | 1 |
| Ligier, F | 1 |
| Weiner, L | 1 |
| Didelot, N | 1 |
| Messaoudi, M | 1 |
| Socha, M | 1 |
| Body-Lawson, F | 1 |
| Kabuth, B | 1 |
| Jensen, PS | 1 |
| Molina, BS | 1 |
| Bukstein, OG | 1 |
| Brown, NV | 1 |
| McNamara, NK | 2 |
| Rundberg-Rivera, EV | 1 |
| Li, X | 1 |
| Kipp, HL | 1 |
| Schneider, J | 1 |
| Farmer, CA | 1 |
| Baker, JL | 1 |
| Sprafkin, J | 1 |
| Rice, RR | 1 |
| Bangalore, SS | 1 |
| Butter, EM | 1 |
| Buchan-Page, KA | 1 |
| Hurt, EA | 1 |
| Austin, AB | 1 |
| Grondhuis, SN | 1 |
| Aman, MG | 5 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Milone, A | 1 |
| Stawinoga, A | 1 |
| Veltri, S | 1 |
| Pisano, S | 1 |
| Moreton, A | 1 |
| Imran, S | 1 |
| Grau, K | 1 |
| Plener, PL | 1 |
| Gahr, M | 1 |
| Denzer, C | 1 |
| Freudenmann, RW | 1 |
| Kálmán, J | 1 |
| Kálmán, S | 1 |
| Pákáski, M | 1 |
| Rothermel, B | 1 |
| Poustka, L | 1 |
| Banaschewski, T | 1 |
| Becker, K | 1 |
| De Smedt, G | 2 |
| Derivan, A | 1 |
| Lyons, B | 1 |
| Snyder, R | 1 |
| Turgay, A | 1 |
| Binder, C | 2 |
| Fisman, S | 1 |
| Carroll, A | 1 |
| Kusumakar, V | 2 |
| Daneman, D | 1 |
| Moshang, T | 1 |
| McDougle, CJ | 1 |
| Scahill, L | 1 |
| McCracken, JT | 1 |
| Tierney, E | 1 |
| Davies, M | 1 |
| Posey, DJ | 1 |
| Martin, A | 1 |
| Ghuman, JK | 1 |
| Shah, B | 1 |
| Chuang, SZ | 1 |
| Swiezy, NB | 1 |
| Gonzalez, NM | 1 |
| Hollway, J | 1 |
| Koenig, K | 1 |
| McGough, JJ | 1 |
| Ritz, L | 1 |
| Vitiello, B | 1 |
| Deberdt, WG | 1 |
| Dysken, MW | 1 |
| Rappaport, SA | 1 |
| Feldman, PD | 1 |
| Young, CA | 1 |
| Hay, DP | 1 |
| Lehman, DL | 1 |
| Dossenbach, M | 1 |
| Degenhardt, EK | 1 |
| Breier, A | 1 |
| LeBlanc, JC | 1 |
| Binder, CE | 1 |
| Armenteros, JL | 1 |
| Wang, JS | 1 |
| Hew, H | 1 |
| Reyes, M | 1 |
| Croonenberghs, J | 1 |
| Augustyns, I | 1 |
| Eerdekens, M | 1 |
| Pandina, GJ | 1 |
| Bilder, R | 1 |
| Harvey, PD | 1 |
| Keefe, RS | 1 |
| Gharabawi, G | 1 |
| Sabuncuoglu, O | 1 |
| Branicky, LA | 1 |
| Schluchter, MD | 1 |
| Lemon, E | 1 |
| Blumer, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Stimulant and Risperidone in Children With Severe Physical Aggression[NCT00796302] | Phase 4 | 168 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00266552] | Phase 3 | 118 participants (Actual) | Interventional | Completed | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00250354] | Phase 3 | 110 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antisocial Behavior Scale (ABS) is a 28-item scale that contains 10 Proactive Aggression items and six Reactive Aggression items. Each item is rated on a 3-point scale, ranging from 1 (Never) to 3 (Very often). Thus, scores on the Reactive Aggression subscale can range from 6 through 18; with higher scores indicating more reactive aggression. (NCT00796302)
Timeframe: Measured at baseline and Week 9
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 15.5 | 11.0 |
| Basic (Stimulant + PMT + Placebo) | 15.9 | 12.3 |
"Using this clinician rating scale the patient's improvement is scored on a 7-point scale which ranges from very much improved (1), through no change (4), to very much worse (7). This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Improvement scores are reported below." (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | ||
|---|---|---|---|
| Much or very much improved at endpoint | Minimally improved at endpoint | Unchanged or worse at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 63 | 11 | 6 |
| Basic (Stimulant + PMT + Placebo) | 58 | 22 | 3 |
Using this clinician rating scale the severity of the illness is scored from 1= normal to 7= extremely ill. This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Severity of Illness scores are reported below. (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | |
|---|---|---|
| Normal/Borderline/Mildly ill at endpoint | Moderately/Markedly/Severely ill at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 56 | 22 |
| Basic (Stimulant + PMT + Placebo) | 49 | 34 |
"Parent ratings of aggression and hostility on the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ) D-Total Score. The NCBRF provides 1 prosocial subscale (Positive/Social) and 6 problem behavior subscales (Conduct Problem, Oppositional Behavior, Hyperactive, Inattentive, Overly Sensitive, and Withdrawn/Dysphoric). The NCBRF has excellent internal consistency, distinguishes between controls and subjects with DBDs. Conduct Problem and Oppositional Behavior subscales map closely to DSM-IV-TR symptoms of CD and ODD; they were scored together to form a variable called the D-Total.~For the NCBRF D-Total, higher scores reflect worse behavior. Each subscale is scored by taking the rating (0 [did not occur or was not a problem] to 3 [occurred a lot or was a very severe problem]) for all component items. The D-Total score was computed by adding the 6 scores from the Oppositional subscale and the 10 items from the Conduct Problem subscale. Thus D-Total scores could range from 0-69." (NCT00796302)
Timeframe: Measured at baseline and Weeks 3, 4, 5, 6, 7, 8, 9
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 42.1 | 25.9 | 17.1 | 12.1 | 13.8 | 13.0 | 11.7 | 10.7 |
| Basic (Stimulant + PMT + Placebo) | 43.5 | 24.9 | 22.4 | 20.1 | 20.7 | 16.8 | 17.8 | 17.8 |
6 reviews available for risperidone and Callous-Unemotional Traits
| Article | Year |
|---|---|
Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Child; Conduct Disorder; Humans; In | 2022 |
Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance.
Topics: Attention Deficit Disorder with Hyperactivity; Combined Modality Therapy; Comorbidity; Conduct Disor | 2021 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
Current pharmacotherapy options for conduct disorders in adolescents and children.
Topics: Adolescent; Aggression; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Central Nervous Sys | 2019 |
[Recognition and treatment of behavioral and psychological symptoms of dementias: lessons from the CATIE-AD study].
Topics: Affect; Aggression; Antipsychotic Agents; Brain; Caregivers; Conduct Disorder; Dementia; Diagnosis, | 2008 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
12 trials available for risperidone and Callous-Unemotional Traits
| Article | Year |
|---|---|
Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Conduct Disorder; Delayed-Action Preparat | 2017 |
Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2019 |
Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Conduct Disorder; Female; Human | 2015 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
Topics: Analysis of Variance; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Chi | 2002 |
Prolactin levels during long-term risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Child, Preschool; Conduct Disorde | 2003 |
Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Communication Disorders; Conduct Disorde | 2005 |
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaze | 2005 |
Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2005 |
Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Behavior; Child; Co | 2006 |
A double-blind pilot study of risperidone in the treatment of conduct disorder.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Conduct Disorder; Dose-Response Relationship, D | 2000 |
12 other studies available for risperidone and Callous-Unemotional Traits
| Article | Year |
|---|---|
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; | 2022 |
Probable Risperidone-Associated Acute Pancreatitis in a Child with ADHD.
Topics: Acute Disease; Attention Deficit Disorder with Hyperactivity; Child; Conduct Disorder; Humans; Pancr | 2022 |
Tardive Oculogyric Crisis With Low-Dose Antipsychotic in an Adolescent: A Case Report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2018 |
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.
Topics: Adolescent; Antipsychotic Agents; Child; Clinical Trials as Topic; Conduct Disorder; Europe; Humans; | 2014 |
Methylphenidate-risperidone combination in child psychiatry: A retrospective analysis of 44 cases.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Conduct Disorder | 2014 |
TOSCA: no longer just an opera.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
A role for risperidone in the treatment of communication disorder and comorbid mental health problems?
Topics: Adolescent; Affective Symptoms; Antipsychotic Agents; Conduct Disorder; Diagnosis, Differential; Fem | 2015 |
Mild Hypothermia in a Child with Low-Dose Risperidone.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Comb | 2017 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
Risperidone and cognitive function in children with disruptive behavior disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2007 |
Risperidone-to-methylphenidate switch reaction in children: three cases.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Attention Deficit and Disruptive Behavior | 2007 |